Trilaciclib

Brand names: Cosela · Active ingredient: Trilaciclib Dihydrochloride

In short: COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

Forms & strengthsFor injection: Contains the equivalent of 300 mg of trilaciclib (provided as 349 mg of trilaciclib dihydrochloride) as a sterile, preservative-free, yellow, lyophilized cake in a single-dose vial for reconstitution and further dilution.
LabelPharmacosmos Therapeutics Inc.
Label updatedSep 10, 2025

What is Trilaciclib used for?

COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

Trilaciclib dosage

The recommended dose of COSELA is 240 mg/m2 per dose. Administer as a 30-minute intravenous infusion completed no more than 4 hours prior to the start of chemotherapy on each day chemotherapy is administered.

The interval between doses of COSELA on sequential days should not be greater than 28 hours.

Missed Treatment Session(s)

If the COSELA dose is missed, discontinue chemotherapy on the day the COSELA dose was missed. Consider resuming both COSELA and chemotherapy on the next scheduled day for chemotherapy.

Discontinuation of Treatment

If COSELA is discontinued, wait 96 hours from the last dose of COSELA before resumption of chemotherapy only.

Dose Modification for Adverse Reactions

Withhold, discontinue, or alter the administration of COSELA to manage adverse reactions as described in Table 1

.

Adverse Reaction | Severity Grade* | Recommended Action

* National Cancer Institute – Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03

Injection-site reactions including phlebitis and thrombophlebitis | Grade 1: Tenderness with or without symptoms (e.g., warmth, erythema, itching) | Interrupt or slow infusion of COSELA. If 0.9% Sodium Chloride Injection, USP is being used as a diluent/flush, consider changing to 5% Dextrose Injection, USP as appropriate for subsequent infusions.

Grade 2: Pain; lipodystrophy; edema; phlebitis | Interrupt infusion of COSELA. If pain not severe, follow instructions for Grade 1. Otherwise, stop infusion in extremity and rotate site of infusion to site in alternative extremity. If 0.9% Sodium Chloride Injection, USP is being used as a diluent/flush, consider changing to 5% Dextrose Injection, USP as appropriate for subsequent infusions. Central access may also be considered.

Grade 3: Ulceration or necrosis; severe tissue damage; operative intervention indicated.ORGrade 4: Life-threatening consequences; urgent interventions indicated. | Stop infusion and permanently discontinue COSELA.

Acute drug hypersensitivity reactions | Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting Activities of Daily Living (ADL). | Stop infusion and hold COSELA until recovery to Grade ≤1 or baseline, then consider resuming COSELA. If Grade 2 recurs, permanently discontinue COSELA.

Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.ORGrade 4: Life-threatening consequences; urgent intervention indicated. | Permanently discontinue COSELA.

Interstitial lung disease/pneumonitis | Grade 2 (symptomatic) | Hold COSELA until recovery to Grade ≤1 or baseline, then consider resuming COSELA.If Grade 2 recurs, permanently discontinue COSELA. …

How to take Trilaciclib — instructions & advice from the label

Injection-Site Reactions, Including Phlebitis and Thrombophlebitis

Inform patients of the signs and symptoms of injection-site reactions, including phlebitis and thrombophlebitis. Advise patients to contact their healthcare provider immediately for signs and symptoms of injection-site reactions, including phlebitis and thrombophlebitis .

Acute Drug Hypersensitivity Reactions

Advise patients to contact their healthcare provider immediately for signs and symptoms of acute drug hypersensitivity reactions including facial, eye, and tongue edema, urticaria, pruritis, and anaphylactic reactions .

Interstitial Lung Disease/Pneumonitis

Advise patients to immediately report new or worsening respiratory symptoms .

Embryo-Fetal Toxicity

Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy .

Advise females of reproductive potential to use effective contraception during treatment with COSELA and for at least 3 weeks after the final dose .

Lactation

Advise women not to breastfeed during treatment with COSELA and for at least 3 weeks after the final dose of COSELA . …

Warnings & precautions

Do not take this medicine if: COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib. Reactions have included anaphylaxis .

COSELA administration can cause injection-site reactions including phlebitis and thrombophlebitis. Injection-site reactions including phlebitis and thrombophlebitis occurred in 56 (21%) of 272 patients receiving COSELA in clinical trials, including Grade 2 (10%) and Grade 3 (0.4%) adverse reactions (ARs). The median time to onset from start of COSELA was 15 days (range 1 to 542) and from the preceding dose of COSELA was 1 day (1 to 15). The median duration was 1 day (range 1 to 151 for the resolved cases). Injection-site reactions including phlebitis and thrombophlebitis resolved in 49 (88%) of the 56 patients and led to discontinuation of treatment in 3 (1%) of the 272 patients.

Monitor patients for signs and symptoms of injection-site reactions, phlebitis, and thrombophlebitis, including infusion-site pain and erythema during infusion. For mild (Grade 1) to moderate (Grade 2) injection-site reactions, flush line/cannula with at least 20 mL of sterile 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP after end of infusion. For severe (Grade 3) or life-threatening (Grade 4) injection-site reactions, stop infusion and permanently discontinue COSELA .

COSELA administration can cause acute drug hypersensitivity reactions, including facial edema and urticaria. Acute drug hypersensitivity reactions occurred in 16 (6%) of 272 patients receiving COSELA in clinical trials, including Grade 2 reactions (2%). One patient experienced a Grade 2 anaphylactic reaction 4 days after receiving COSELA, which resolved with epinephrine, and treatment with COSELA was continued. …

Trilaciclib side effects

The following clinically significant adverse reactions are described elsewhere in the label:

Injection-Site Reactions, including phlebitis and thrombophlebitis

Acute Drug Hypersensitivity Reactions

ILD/Pneumonitis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of COSELA was evaluated in Studies 1, 2, and 3 . Patients received COSELA 240 mg/m2 by 30-minute intravenous infusion prior to chemotherapy on each chemotherapy day. The data described in this section reflect exposure to COSELA among 240 patients (122 patients in the trilaciclib group and 118 patients in the placebo group) being treated for extensive stage-small cell lung cancer (ES-SCLC) in 3 randomized, double-blind, placebo-controlled trials: 32 patients with treatment naïve ES-SCLC received carboplatin (AUC 5 Day 1) + etoposide (100 mg/m2 Days 1-3) every 21 days; 58 received carboplatin (AUC 5 Day 1) + etoposide (100 mg/m2 Days 1-3) every 21 days + atezolizumab (1200 mg on Day 1) every 21 days; 32 patients with previously treated ES-SCLC received topotecan (1.5 mg/m2 Days 1-5) every 21 days. …

Drug interactions

COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e.g., dofetilide, dalfampridine, and cisplatin) .

Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA.

Drugs | Recommendations | Comments

Dofetilide | The potential benefits of taking COSELA concurrently with dofetilide should be considered against the risk of QT interval prolongation. | Increased dofetilide blood levels may occur in patients who are also receiving COSELA. Increased plasma concentrations of dofetilide may cause serious ventricular arrhythmias associated with QT interval prolongation, including torsade de pointes.

Dalfampridine | The potential benefits of taking COSELA concurrently with dalfampridine should be considered against the risk of seizures in these patients. | Increased dalfampridine blood levels may occur in patients who are also receiving COSELA. Elevated levels of dalfampridine increase the risk of seizure.

Cisplatin | Closely monitor for nephrotoxicity. …

About this medicine

COSELA for injection contains trilaciclib dihydrochloride, a kinase inhibitor.

The chemical name for trilaciclib is 2'-{[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino}-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one.

Trilaciclib dihydrochloride is a water-soluble yellow solid, with molecular formula of C24H30N8O•2HCl, a molecular weight of 519.48 g/mol (Free base: 446.56 g/mol), and the following chemical structure:

COSELA (trilaciclib) for injection is a sterile, preservative-free, yellow lyophilized cake in a single-dose vial for intravenous infusion after reconstitution and dilution.

Each single-dose vial contains the equivalent of 300 mg of trilaciclib (provided as 349 mg of trilaciclib dihydrochloride) and the following inactive ingredients: citric acid monohydrate (75.6 mg) and mannitol (300 mg); hydrochloric acid and sodium hydroxide to adjust pH.

How it works: Trilaciclib is a transient inhibitor of CDK 4 and 6. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b3179c19-78f3-4bf1-b73e-7f7638522ab1. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate